GI CANCERS

Neoadjuvant PAXG led to a significant improvement in event-free survival vs mFOLFIRINOX in resectable or borderline resectable pancreatic ductal adenocarcinoma.

Adjuvant nivolumab offered sustained survival benefits in resected esophageal/GEJ cancer post chemoradiation, with PD-L1 emerging as a potential biomarker.

Durvalumab plus FLOT improved event-free survival vs placebo in resectable gastric/GEJ cancer.

In the phase 3 PANOVA-3 trial, patients who underwent tumor-treating fields therapy had extended overall survival vs standard-of-care gemcitabine plus nab-paclitaxel.

A 3-year structured exercise program significantly improved DFS and OS in stage II/III CRC, reducing recurrence by 28% and death risk by 37%.

Less inflammatory diets were linked to improved overall survival in stage III colon cancer, and physical activity showed synergistic benefits.

The next-generation KRAS G12C inhibitor MK-1084 showed promising efficacy and safety as a single agent and in combinations for advanced colorectal cancer.

DNA methylation, RTK pathway changes, and KRAS amplifications may drive resistance to sotorasib plus panitumumab in KRAS G12C colorectal cancer.

Escalated adjuvant chemotherapy, guided by ctDNA, did not improve recurrence-free survival for stage III colon cancer patients, per DYNAMIC-III trial.

Nivolumab plus ipilimumab shows durable survival benefit over chemotherapy and monotherapy in mismatch repair-deficient colorectal cancer.

Anlotinib plus chemotherapy has emerged as a first-line alternative to bevacizumab/chemotherapy in RAS/BRAF wild-type metastatic colorectal cancer.

The BREAKWATER trial showed encorafenib, cetuximab, & mFOLFOX6 significantly improved PFS and OS in first-line BRAF V600E-mutant mCRC.

T-DXd significantly improved overall survival vs ramucirumab/paclitaxel in second-line HER2-positive unresectable/metastatic gastric/GEJ cancer.

Terence M. Williams, MD, PhD, discussed the phase 1 DINOMITE trial of radiation therapy and papaverine in rectal cancer at City of Hope.

EBC-129 has been granted FDA fast track designation for the treatment of pancreatic ductal adenocarcinoma, paving the way for development of this antibody-drug conjugate.

Terence M. Williams, MD, PhD, discusses what inspired the new phase 1 DINOMITE trial at City of Hope.

In an interview, Arvind Bussetty, MD, and Arvind Trindade, MD, delved into the rising rates of gastrointestinal cancers among younger patients.

The phase 3 IDeate-Esophageal01 study of ifinatamab deruxtecan has dosed its first patient with esophageal squamous cell carcinoma.

Panitumumab combined with FOLFOX improves survival and reduces recurrence in RAS/BRAF wild-type locally advanced colon cancer.

Yelena Y. Janjigian, MD, discusses how to manage the potential adverse events of pembrolizumab when using the recently approved combination of pembrolizumab plus trastuzumab and chemotherapy.

A groundbreaking study reveals the potential of CISH inhibition in enhancing immunotherapy for metastatic colorectal cancer, showcasing promising patient responses.

In interviews with Targeted Oncology, Ronan J. Kelly, MD, MBA, and David Zhen, MD, discuss the CheckMate 649 trial of nivolumab plus ipilimumab and look back on last year's ODAC meeting on its use in PD-L1–negative gastrointestinal cancers.

Arvind Trindade, MD, discusses a large database study looking at rising rates of pancreatic and colon cancer in young adults.